TiGenix reports success for AlloCSC-01 in Phase I/II heart failure study

TiGenix, a Belgium-based biopharmaceutical company, has announced promising results from its Phase I/II study assessing the safety and efficacy of AlloCSC-01, its innovative stem cell ... Read More